Japanese pharmaceutical company Astellas decided to stop selling the antibiotic josamycin (vilprafen) in Russia. But this has nothing to do with the conflict in Ukraine and anti-Russian sanctions. RIA News said the company’s press service.
As the organization explained to journalists, the antibiotic will cease to be supplied not only to the Russian Federation, but also to the global market as a whole, and the reason for this is the optimization of Astellas investments. Moreover, this situation was reported in 2020 and the company discussed with the Ministry of Health about withdrawing the drug from the Russian market. The discussion led to an agreement that the cessation of sales would occur in two phases, in 2024 and 2026.
Next year, vilprafen will no longer be sold in film-coated tablet or suspension form. From now on, Vilprafen Solutab dissolvable tablets will be available in the Russian Federation for another two years. Imports will be stopped in 2026.
Previously at the Russian Ministry of Health reportedJosamycin in Russian pharmacies can be replaced by azithromycin and clarithromycin.
Immunologists before saidHow does the lack of vilprafen in pharmacies threaten Russians?